


## PTseq™ plus Entire-process Detection



### One-stop next-generation sequencing sample preparation workstation

MGIFLP-L Automatic sample preparation system



Throughput: 4 - 32 samples/run

#### Highly integrated

The entire process of sample extraction, library construction, DNB preparation, and quality control is integrated to achieve "Sample in, DNB out"

#### Easy to use

Equipped with user-friendly master control software and preset applications for easy operation, **supporting one-click startup**

#### Safety and pollution prevention

Integrated with HEPA high-efficiency filtration system and UV function, **ensuring safety and pollution prevention**

#### Excellent performance

A **100% Pass rate** of wet lab QC, a **99% pass rate** of full-process QC, within-run and between-run precision >98%

### Multiple sequencing platforms for diverse clinical needs



#### MGISEQ-G50 platform

- ★ Single chip, with data volume of 600M/chip
- ★ Sequencing time: 7h
- ★ PTseq™ plus supports up to 48 samples/chip
- ★ Supports mixed mNGS and tNGS sample sequencing



#### DNBSEQ-G99 platform

- ★ Dual chips, with data volume of 100M/chip
- ★ Sequencing time: 3.5h
- ★ PTseq™ plus supports up to 32 samples/chip
- ★ Supports mixed mNGS and tNGS sample sequencing
- ★ Flexible, supporting simultaneous/rolling loading of dual chips



#### DNBSEQ-E25 platform

- ★ Single chip, with data volume of 25M/chip
- ★ Sequencing time: 4h
- ★ PTseq™ plus supports up to 12 samples/chip
- ★ Cover an area of only 0.1 m², and movable
- ★ Integrated kit, no washing required

### Intelligent Integrated Local Analysis and Interpretation System

HALOS All-in-one Bioinformatic Analyzer



#### Comprehensive and thorough

Built-in with multiple analysis software for pathogen detections, **one machine with multiple functions**. The software covers multiple functional modules such as sample management, analysis & interpretation, data statistics, etc., **enabling entire-process management**

#### Easy to use

Truly **unattended operation**, with sequencing data automatically pushed to the all-in-one machine for automated analysis and reporting

#### Flexible and efficient

Support **multiple functions** such as HIS/LIS system integration, establishment of local literature database and background strain database, and personalized report configuration

#### Safe and reliable

Local network design, equipped with **Level 3 network system security certification**, strict account permission settings, ensuring maximum data security

[www.bgi.com/global/](http://www.bgi.com/global/)  
[info@bgi.com](mailto:info@bgi.com)

**For Research Use Only. Not for use in diagnostic procedures.**

For a complete listing of our global offices, please visit [www.bgi.com/global/](http://www.bgi.com/global/).  
Copyright ©2025 BGI. All rights reserved. The BGI logo is trademark of BGI. All trademarks are the property of BGI, or their respective owners.  
Information, descriptions and specifications in this publication are subject to change without notice.  
Published April 2025.

Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please contact a representative for regional availability.  
The company reserves the right of final interpretation.

**BGI**



@BGI\_Genomics

**BGI**


## PTseq™ Pan-infection Pathogen Targeted Sequencing PTseq™ plus

Comprehensive and Efficient Identification of **859** Clinical Infection Pathogenic Microorganism, Drug Resistance Genes, and Virulence Genes




Product Introduction

PTseq™ Pan-infection Pathogen Targeted Sequencing (PTseq™ plus) is based on the targeted next-generation sequencing (tNGS) technology, which captures the target sequences of specific pathogenic microorganisms by probe hybridization, followed by sequencing on next-generation sequencing platform. This product covers a total of 859 targets, including 729 carefully selected pathogenic microorganisms and 130 drug resistance/virulence genes tailored for respiratory, bloodstream, central nervous system, and other infection syndromes. It can efficiently identify suspected infectious pathogens such as bacteria, fungi, and viruses, along with drug resistance and virulence genes, covering over 98% of clinical infection scenarios. It significantly enhances the positive rate of pathogen diagnosis, reduces the risk of drug resistance, and supports precise diagnosis and treatment of infections.




Detection scope



Target audience

- Individuals who are clinically suspected of being infected by pathogenic microorganisms and need to know the cause of infection
- Patients requiring drug resistance gene identification


Applicable scenarios



Product Advantages


Broad-spectrum coverage, identification of pathogenic microorganisms

- A single test fully **covers 729** kinds of clinically significant pathogen targets
- All-round drug resistance identification of **bacteria, fungi, and viruses**




High-Density Probe · Precision Capture

- Hundreds of thousands of high-density probes enable **multi-target coverage**, with higher probe density provided for clinically significant and difficult-to-inspect pathogens to ensure the test sensitivity.
- Adoption of the **integrated probe design for all representative strains is adopted**, retaining multiple overlapping probes in hyper-variable regions, and eliminating redundant probes in conserved regions, **enabling efficient capture**.
- Full-length coverage of drug resistance and virulence genes** sequences, with higher probe density at drug resistance mutation sites, enhancing the sequencing depth and detection accuracy of **drug resistance sites**.



Multidimensional Think Tank · Empowering Clinical Practices

- Construction of a clinical **pathogen sequence database**, **species annotation database**, and **background bacteria database** adapted to various samples, enabling precise identification of pathogenic microorganisms
- Provision of **comprehensive annotation information for the detected drug resistance and virulence genes**, assisting in addressing the clinical application challenges of drug resistance gene detection, and enhancing the reference value of drug resistance results
- Self-built COVID-19 subtype database**, updated in real-time to ensure subtyping accuracy



Efficient Detection · Outstanding Performance

- Realization of ultra-sensitive detection through capture and enrichment, with a detection limit as low as **10 CFU(copies)/mL**.
- High-efficiency cell-free DNA fragment enrichment capability, improving the detection sensitivity in samples such as **blood and cerebrospinal fluid**. Compared with multiplex PCR targeted sequencing, the **positive detection rate of sterile body fluid samples increases by 15% to 20%**.
- 1h rapid hybridization technology**, significantly improving hybridization efficiency and speed, and reducing the detection time

|                    | Gram-positive bacteria   |                                    |               | Gram-negative bacteria  |                      |                      | Fungi            |                       | DNA viruses               | RNA viruses                |
|--------------------|--------------------------|------------------------------------|---------------|-------------------------|----------------------|----------------------|------------------|-----------------------|---------------------------|----------------------------|
| Pathogen           | Streptococcus agalactiae | Mycobacterium tuberculosis complex | Nocardia nova | Acinetobacter baumannii | Klebsiella aerogenes | Bordetella pertussis | Candida albicans | Aspergillus fumigatus | Human herpesvirus 5 (CMV) | Parainfluenza virus type 3 |
| LOD CFU(copies)/mL | 50                       | 50                                 | 50            | 50                      | 10                   | 50                   | 100              | 10                    | 10                        | 0.0135 TCID*               |

\* TCID: A measuring unit for characterizing virus titer, the amount of virus required to cause half of the cells to become diseased or die in a 50-well plate or test tube

Sample Types

| Sample Type                       | Recommended sampling volume                                                                      | Collection tube                          |
|-----------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------|
| Peripheral blood                  | Adults: ≥3 mL; Infants: ≥2 mL                                                                    | Disposable cell-free DNA collection tube |
| Bronchoalveolar lavage fluid      | ≥3mL                                                                                             | Sterile and clean cryovial               |
| Sputum                            | ≥3 mL (deep sputum)                                                                              | Sterile and clean cryovial               |
| Nasopharyngeal/Oropharyngeal swab | 1-2 pcs                                                                                          | Disposable virus sampling kit            |
| Cerebrospinal fluid               | ≥2mL                                                                                             | Sterile and clean cryovial               |
| Pus, pleural/ascitic fluids, etc. | ≥3mL                                                                                             | Sterile and clean cryovial               |
| Fresh tissue                      | Tissue obtained through surgery Mung bean-sized; tissue obtained through puncturing: 2-3 needles | Sterile and clean cryovial               |

PTseq™ plus One-stop Localization Solutions

